Senior Vice President, Regulatory Affairs · Supernus Pharmaceuticals, Inc. (SUPN)

Tami Martin

A named executive officer of Supernus Pharmaceuticals in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$843,157

Salary $336,200Stock awards $45,675

FY2020: $804,637

5th of 5 named executive officers at Supernus Pharmaceuticals by FY2021 total.

5 named officers on file for Supernus Pharmaceuticals, FY2021

Tami Martin’s pay file — $29

  • 5 fiscal years of pay, line by line
  • SUPN’s disclosed peer group of 29 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Supernus Pharmaceuticals’s whole pay program stands against its peers

  • Supernus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SUPN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 2, 2022 (DEF 14A).

Free

Get Tami Martin’s full pay file as a PDF — free

More than this page: up to 10 years of Tami’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Tami Martin compensation by year

Supernus Pharmaceuticals Summary Compensation Table · all 5 fiscal years held
In US dollars, as Supernus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021
Salary$298,700$307,661$316,891$326,401$336,200
Bonus$0$0$0$0—
Stock awards$0$0$0$0$45,675
Option awards$244,719$278,326$424,540$309,438$288,981
Non-equity incentive$84,413$98,622$91,400$131,200$129,700
Pension and deferred compensation$0$0$0$0—
All other$43,125$40,430$41,988$37,598$42,601
Total$670,957$725,039$874,819$804,637$843,157

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Supernus Pharmaceuticals, Inc. DEF 14A filed May 2, 2022, accession 0001104659-22-054617, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Supernus Pharmaceuticals, Inc. filed document, accession 0001104659-22-054617. Every figure is read from that document and cited to the page and table it appears in. Filed May 2, 2022.

$671K
$725K
$875K
$805K
$843K
FY17
FY18
FY19
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU1,500$43,740—
Option16,500—$23.99
Option10,000—$36.75
Option17,000—$29.61
Option3,000—$39.40

Per the Outstanding Equity Awards at Fiscal Year-End table in Supernus Pharmaceuticals, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Supernus Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Jack KhattarChief Executive Officer, President & Secretary$8,116,721
Timothy DecSenior Vice President, Chief Financial Officer$1,453,535
Jonathan RubinSenior Vice President, Chief Medical Officer Research and Development$1,028,349
Padmanabh BhattSenior Vice President, Intellectual Property, Chief Scientific Officer$933,265
Tami Martin · this pageSenior Vice President, Regulatory Affairs$843,157

The full Supernus Pharmaceuticals compensation record

free company brief

This page is one person within Supernus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Supernus Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Supernus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Tami Martin's compensation dossier · One-time report. No refunds.